NDAORALCAPSULEPriority Review
Approved
May 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ridaura (auranofin) is an oral gold-based disease-modifying antirheumatic drug (DMARD) approved in 1985 for rheumatoid arthritis. It works through immunosuppressive mechanisms believed to involve gold salt accumulation in affected tissues. This represents a legacy oral therapy in a modern treatment landscape dominated by biologics.
$0.99MPart D
LOE ApproachingMinimal commercial investment justified; core team likely focused on managing decline rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Auranofin for Giardia Protozoa
Started Nov 2016
93 enrolled
Amoebic DysenteryGiardiasis
Auranofin PK Following Oral Dose Administration
Started Apr 2014
15 enrolled
Amoebiasis
Career Relevance
Working on Ridaura offers minimal career growth within the pharmaceutical industry; the product commands near-zero linked job openings and operates in a managed decline phase. Career advancement would require transition to growth-stage therapeutics or pivot to operational/compliance roles focused on maximizing margin on a shrinking franchise.
Product Manager (legacy portfolio)
Worked on RIDAURA at Enterprise Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.